Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
03 November 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
- Medicare product coverage strategy
- Proper planning for product pricing
- Preparing comparative effectiveness data
- Working with payer expectations
- Data that should be in place for partnering or acquisition deals
Panelists:
- Judith A. Waltz, Partner, Foley & Lardner LLP
- Anita Chawla, Ph.D., Vice President, Analysis Group
- Antoun Nabhan, Director of Corporate Development, Onyx Pharmaceuticals
Related Insights
30 August 2024
Viewpoints
FTC’s Ban on Noncompete Agreements Is Blocked
04 September 2024
Events
Navigating Intellectual Property While Building with AI
Foley Partner Eric Sophir will present on the topic of “Navigating Intellectual Property while building with AI” at the Martin Luther King Jr. Memorial Library on Wednesday, September 4, 2024, from 4:00 p.m.-5:00 p.m. EDT.
29 August 2024
Manufacturing Industry Advisor
2024 CPSC and FDA Enforcement Trends
The enforcement trends of 2023 have continued into 2024, especially with respect to the U.S. Consumer Product Safety Commission and the U.S. Food and Drug Administration.